Global Drug Based on Gene Therapy Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Drug Based on Gene Therapy Market Insights, Forecast to 2034
Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery.
Market Analysis and InsightsGlobal Drug Based on Gene Therapy Market
Global Drug Based on Gene Therapy market is expected to reach to US$ 11590 million in 2024, with a positive growth of %, compared with US$ 9063.6 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Drug Based on Gene Therapy industry is evaluated to reach US$ 49770 million in 2029. The CAGR will be 27.5% during 2024 to 2029.
The Drug Based on Gene Therapy market is primarily driven by the revolutionary potential of gene therapy to address genetic disorders at their root cause, offering a new paradigm for treating previously incurable conditions. Gene therapy involves introducing genetic material into a patient's cells to correct or replace faulty genes, aiming to restore normal cellular function. The increasing understanding of the genetic basis of diseases, coupled with advancements in gene delivery methods and genome editing techniques, contributes to market growth. Moreover, the demonstrated benefits of gene therapy in providing targeted and long-lasting treatments, overcoming limitations of traditional pharmacological approaches, and offering hope to patients with rare genetic disorders further propel adoption. However, challenges include optimizing gene delivery efficiency, addressing potential immune responses, and ensuring the long-term safety and durability of gene-based treatments. Navigating regulatory pathways, conducting rigorous clinical trials, and addressing ethical considerations are ongoing concerns. The market's success relies on continuous research in genetic medicine, collaborations between biotechnology companies and research institutions, and comprehensive education on the benefits and potential challenges of using gene therapy-based drugs while addressing the evolving challenges associated with precision medicine and personalized treatments.
Report Covers
This report presents an overview of global Drug Based on Gene Therapy market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Drug Based on Gene Therapy market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
Biogen
Novartis
Gilead Sciences
Sarepta Therapeutics
Alnylam Pharmaceuticals
Amgen
Spark Therapeutics
Akcea Therapeutics
bluebird bio
Sunway Biotech
SIBIONO
AnGes
Orchard Therapeutics
Human Stem Cells Institute
Segment by Type
Viral Gene Therapy
Non-viral Gene Therapy
Neurological Diseases
Cancer
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, Drug Based on Gene Therapy introduction, etc. Drug Based on Gene Therapy Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports Conclusions of Drug Based on Gene Therapy
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports
Market Analysis and InsightsGlobal Drug Based on Gene Therapy Market
Global Drug Based on Gene Therapy market is expected to reach to US$ 11590 million in 2024, with a positive growth of %, compared with US$ 9063.6 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Drug Based on Gene Therapy industry is evaluated to reach US$ 49770 million in 2029. The CAGR will be 27.5% during 2024 to 2029.
The Drug Based on Gene Therapy market is primarily driven by the revolutionary potential of gene therapy to address genetic disorders at their root cause, offering a new paradigm for treating previously incurable conditions. Gene therapy involves introducing genetic material into a patient's cells to correct or replace faulty genes, aiming to restore normal cellular function. The increasing understanding of the genetic basis of diseases, coupled with advancements in gene delivery methods and genome editing techniques, contributes to market growth. Moreover, the demonstrated benefits of gene therapy in providing targeted and long-lasting treatments, overcoming limitations of traditional pharmacological approaches, and offering hope to patients with rare genetic disorders further propel adoption. However, challenges include optimizing gene delivery efficiency, addressing potential immune responses, and ensuring the long-term safety and durability of gene-based treatments. Navigating regulatory pathways, conducting rigorous clinical trials, and addressing ethical considerations are ongoing concerns. The market's success relies on continuous research in genetic medicine, collaborations between biotechnology companies and research institutions, and comprehensive education on the benefits and potential challenges of using gene therapy-based drugs while addressing the evolving challenges associated with precision medicine and personalized treatments.
Report Covers
This report presents an overview of global Drug Based on Gene Therapy market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Drug Based on Gene Therapy market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
By Company
Biogen
Novartis
Gilead Sciences
Sarepta Therapeutics
Alnylam Pharmaceuticals
Amgen
Spark Therapeutics
Akcea Therapeutics
bluebird bio
Sunway Biotech
SIBIONO
AnGes
Orchard Therapeutics
Human Stem Cells Institute
Segment by Type
Viral Gene Therapy
Non-viral Gene Therapy
Segment by Application
Neurological Diseases
Cancer
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, Drug Based on Gene Therapy introduction, etc. Drug Based on Gene Therapy Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports Conclusions of Drug Based on Gene Therapy
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports